Compare Quest Diagnostics Inc (DGX) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI United Kingdom (FTSE) — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while iShares MSCI United Kingdom (FTSE) trades at $46.48 (market cap $3.62B). The key difference: Quest Diagnostics Inc is far larger — about 7× iShares MSCI United Kingdom (FTSE)'s market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares MSCI United Kingdom (FTSE) for 46 Days on average.
| DGX | EWU | |
|---|---|---|
Market Cap | $25.48B | $3.62B |
Volume | 941,866 | 923,896 |
Sector | Health | Broad Market / Factor |
52-Week High | $247.45 | $49.39 |
52-Week Low | $173.49 | $41.34 |
Typical Hold Time | 56 Days | 46 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
EWU trades at $46.445, up 1.12% on the day, but faces a bearish technical outlook with 16 sell signals versus 3 buy signals. The stock is trading near key support levels at $46, with RSI indicators showing mixed signals. Recent UK market volatility driven by rising gilt yields and inflation concerns creates headwinds for this UK-focused ETF.
The outlook remains cautious given the bearish technical momentum and macroeconomic pressures from rising UK borrowing costs. Investment opportunity exists for contrarian investors if support holds, but risks include further interest rate hikes and economic uncertainty in the UK market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
